Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

524 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advanced prostate cancer 2010: what a year!
Sartor O, Vogelzang N. Sartor O, et al. Clin Genitourin Cancer. 2010 Dec 1;8(1):8-9. doi: 10.3816/CGC.2010.n.001. Clin Genitourin Cancer. 2010. PMID: 21208849 No abstract available.
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.
Eisenberger MA, Laufer M, Vogelzang NJ, Sartor O, Thornton D, Neubauer BL, Sinibaldi V, Lieskovsky G, Carducci MA, Zahurak M, Raghavan D. Eisenberger MA, et al. Among authors: sartor o. Urology. 2004 Jan;63(1):114-9. doi: 10.1016/j.urology.2003.08.017. Urology. 2004. PMID: 14751361 Clinical Trial.
Assessing progress against prostate cancer.
Sartor O, Alchalabi T, Figg WD. Sartor O, et al. Clin Genitourin Cancer. 2006 Sep;5(2):102-3. doi: 10.3816/CGC.2006.n.025. Clin Genitourin Cancer. 2006. PMID: 17026796 No abstract available.
Chemotherapy in prostate cancer: an update.
Sartor O. Sartor O. Clin Genitourin Cancer. 2007 Jun;5(5):304-5. doi: 10.3816/CGC.2007.n.008. Clin Genitourin Cancer. 2007. PMID: 17645826 No abstract available.
Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antigen level, and prior ADT exposure with duration of ADT effect.
Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Ross RW, et al. Among authors: sartor o. Cancer. 2008 Mar 15;112(6):1247-53. doi: 10.1002/cncr.23304. Cancer. 2008. PMID: 18293426 Free article. Clinical Trial.
524 results